Researchers track Real-World MS treatment use and patient experience
NCT ID NCT05090033
Summary
This completed study looked at how people in Australia with relapsing multiple sclerosis (MS) used a treatment called Kesimpta (ofatumumab) in their daily lives. It tracked if patients took their doses on time and explored how the treatment affected their fatigue, work productivity, and overall satisfaction. The goal was to understand real-world treatment patterns and patient experiences, not to test if the drug works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Concord, New South Wales, 2139, Australia
-
Novartis Investigative Site
Southport, Queensland, 4222, Australia
-
Novartis Investigative Site
Clayton, Victoria, 3168, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Nedlands, Western Australia, 6009, Australia
-
Novartis Investigative Site
Heidelberg, 3084, Australia
-
Novartis Investigative Site
St Leonards, 2065, Australia
Conditions
Explore the condition pages connected to this study.